Cardiome Pharma Corp. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: December 1, 2016
Pages: 50
Price:
US$ 499.00
Cardiome Pharma Corp. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)
ID: C6E97C209A0BEN
Leaflet:

Download PDF Leaflet

Cardiome Pharma Corp. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Cardiome Pharma Corp. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Cardiome Pharma Corp. and its competitors. This provides our Clients with a clear understanding of Cardiome Pharma Corp. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Cardiome Pharma Corp. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Cardiome Pharma Corp.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Cardiome Pharma Corp. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Cardiome Pharma Corp. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Cardiome Pharma Corp. business.

About Cardiome Pharma Corp.

Cardiome Pharma Corp., a life sciences company, focuses on developing drugs to treat or prevent cardiovascular diseases. The company’s drug development activities are focused on the treatment of atrial arrhythmias; a Phase 1 program for GED-aPC, an engineered analog of human activated protein C; and a pre-clinical program directed at improving cardiovascular function.

Products in Development

Vernakalant for Atrial Fibrillation

Vernakalant is a new chemical entity designed to treat atrial fibrillation, with the potential to overcome the limitations of current drugs used to treat the disease. Its mechanism of action involves the selective blockade of multiple ion channels in the heart that are known to be active during episodes of atrial fibrillation. The drug is being developed for two potential applications: vernakalant, is being evaluated as an intravenous pharmacological converting agent designed to terminate an atrial fibrillation episode and return the heart to normal rhythm; and vernakalant (oral) is being evaluated as an oral maintenance therapy for the long-term prevention of atrial fibrillation recurrence.

Vernakalant

Vernakalant (oral) is being evaluated as an oral maintenance therapy for the long-term prevention of atrial fibrillation recurrence. Together with collaboration partners, Astellas, who has marketing rights to vernakalant in Canada, the United States and Mexico, and Merck, who has marketing rights to the rest of the world, the company involves in the development of vernakalant, a product candidate for the treatment of atrial fibrillation.

Astellas also conducted an open-label safety study in patients with atrial fibrillation, or ACT 4, in order to gather additional safety data, which has completed. In October 2009, Astellas initiated enrollment in a single confirmatory additional Phase 3 clinical trial, ACT 5. In December 2009, the company announced that the Phase 3 European comparator (AVRO) study was completed and met its primary endpoint.

Merck Collaboration

In April 2009, the company entered into a collaboration and license agreement with Merck & Co., Inc., or Merck, for the development and commercialization of vernakalant. The agreement provides an affiliate of Merck with global rights to vernakalant (oral) and exclusive rights outside of the United States, Canada and Mexico to vernakalant. The company has also retained an option to co-promote vernakalant (oral) with Merck through a hospital-based sales force in the United States.

Astellas Collaboration

The company, in October 2003, entered into a collaboration and license agreement with Astellas, a U.S. affiliate of Astellas Pharma Inc., a pharmaceutical company headquartered in Japan. The company granted Astellas a license to vernakalant and its related technology to develop, make, and sell intravenous or injectable formulations of vernakalant in North America for any and all indications, including the treatment of atrial fibrillation and atrial flutter, including a right to sublicense to third parties.

Competition

The company’s competitors include Boston Scientific, Johnson & Johnson, Medtronic, Pfizer, Sanofi-Aventis, Astra Zeneca, Glaxo SmithKline and Novartis.

History

The company was founded in 1986. It was formerly known as Nortran Resources Ltd. and changed its name to Nortran Pharmaceuticals Inc. in 1992. Further, the company changed its name to Cardiome Pharma Corp. in 2001.


The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

RESEARCH METHODOLOGY

DISCLAIMER

1. CARDIOME PHARMA CORP. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. CARDIOME PHARMA CORP. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. CARDIOME PHARMA CORP. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. CARDIOME PHARMA CORP. FINANCIAL ANALYSIS

4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. CARDIOME PHARMA CORP. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Cardiome Pharma Corp. Direct Competitors
5.2. Comparison of Cardiome Pharma Corp. and Direct Competitors Financial Ratios
5.3. Comparison of Cardiome Pharma Corp. and Direct Competitors Stock Charts
5.4. Cardiome Pharma Corp. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Cardiome Pharma Corp. Industry Position Analysis

6. CARDIOME PHARMA CORP. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. CARDIOME PHARMA CORP. EXPERTS REVIEW1

7.1. Experts Opinion
7.2. Experts Estimates

8. CARDIOME PHARMA CORP. ENHANCED SWOT ANALYSIS2

9. CANADA PESTEL ANALYSIS2

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. CARDIOME PHARMA CORP. IFE, EFE, IE MATRICES2

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. CARDIOME PHARMA CORP. PORTER FIVE FORCES ANALYSIS2

12. CARDIOME PHARMA CORP. VRIO ANALYSIS2


APPENDIX: RATIO DEFINITIONS


LIST OF TABLES

Cardiome Pharma Corp. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Cardiome Pharma Corp. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Cardiome Pharma Corp. Major Shareholders
Cardiome Pharma Corp. History
Cardiome Pharma Corp. Products
Revenues by Segment
Revenues by Region
Cardiome Pharma Corp. Offices and Representations
Cardiome Pharma Corp. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Cardiome Pharma Corp. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Cardiome Pharma Corp. Capital Market Snapshot
Cardiome Pharma Corp. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Cardiome Pharma Corp. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Cardiome Pharma Corp. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1

LIST OF FIGURES

Cardiome Pharma Corp. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Cardiome Pharma Corp. 1-year Stock Charts
Cardiome Pharma Corp. 5-year Stock Charts
Cardiome Pharma Corp. vs. Main Indexes 1-year Stock Chart
Cardiome Pharma Corp. vs. Direct Competitors 1-year Stock Charts
Cardiome Pharma Corp. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.


PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.


Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top


Ask Your Question

Cardiome Pharma Corp. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: